



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Letter to Editor

SARS-CoV-2 mRNA vaccination, prostate cancer and steroids: Correspondence

Dear Editor, we would like to correspond on the publication “Humoral response after SARS-CoV-2 mRNA vaccination in patients with prostate cancer using steroids [1].” Ishii et al. reported that individuals who used steroids concurrently had considerably poorer humoral responses to the BNT162b2 mRNA vaccination. The presence of CRPC, the accumulation of post-CRPC treatments, and steroid use all had an impact on anti-SARS-CoV-2 S antibody titers [1]. The most recent study provides new data and may suggest the value of the immunization. The response to vaccination in patients with underlying diseases and those taking personal medications may vary from that of the general, healthy vaccine recipient.

We all concur that giving the COVID-19 vaccine should be advantageous. The results of the current study indicate that vaccination history points to a protective effect of the COVID-19 vaccine. However, another potential exacerbating factor is the relatively common antecedent COVID-19 without symptoms [2]. In most cases, no testing is done to rule out the potential of earlier asymptomatic COVID-19. The outcomes of the injection of the COVID-19 vaccine

can be more precisely predicted if the pre-existing immunological conditions of the participants are properly evaluated.

Conflicts of Interest

None.

Rujittika Mungmunpantipantip, PhD^{a,*}

Viroj Wiwanitkit, MD^b

^a Private Academic Consultant, Bangkok Thailand

^b Dr DY Patil Medical College, Pune, India

E-mail address: rujittika@gmail.com

(R. Mungmunpantipantip)

*Corresponding author. Tel.: 62678273728222

References

- [1] Ishii N, Hatakeyama S, Yoneyama T, Tanaka R, Narita T, Fujita N, et al. Humoral response after SARS-CoV-2 mRNA vaccination in patients with prostate cancer using steroids. *Urol Oncol* 2022. <https://doi.org/10.1016/j.urolonc.2022.07.015>:S1078-1439(22)00273-3 Online ahead of print.
- [2] Joob B, Wiwanitkit V. Letter to the Editor: Coronavirus Disease 2019 (COVID-19), infectivity, and the incubation period. *J Prev Med Public Health* 2020;53(2):70.:Mar1.